Back to Journals Neuropsychiatric Disease and Treatment Volume 22 Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis Authors Kumar R , Hashempour Z, Shahriarirad S, Shahriarirad R, Hassett LC, Singh B , Croarkin PE , Veldic M, Frye MA, Pagali SR Received 6 January 2026 Accepted for publication 12 March 2026 Published 3 June 2026 Volume 2026:22 586506 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Roger Pinder Rakesh Kumar, 1 Zahra Hashempour, 2 Sara Shahriarirad, 2 Reza Shahriarirad, 3 Leslie C Hassett, 4 Balwinder Singh, 1 Paul E Croarkin, 1 Marin Veldic, 1 Mark A Frye, 1 Sandeep R Pagali 5 1 Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA
Should you be concerned
Treatment with Pharmacological peroxisome proliferator-activated receptor agonist Clofibrate increases intestinal carnitine absorption in rats
Other earlier studies have also found similar results
5 The organization is careful to note that except in the case of evidence of subclinical disease defining the presence of ASCVD, reclassification to a higher risk category is a matter of clinical judgment. 5 The guidelines reference the JUPITER trial, as described above, in their consideration of additional cardiovascular risk factors, but do not provide further evaluation of the evidence
